About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, September 20th, 2017

The QualityStocks
Daily Stock List


Delcath Systems, Inc. (DCTH)

Stocktwits, SuperStockScreener, TradingView, MarketWatch, OTC Markets, Barchart, Invest, Morningstar, Stock News Journal, and StocksGallery, 4-Traders, and Insider Financial reported on Delcath Systems, Inc. (DCTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Delcath Systems, Inc. is an interventional oncology Company centered on the treatment of primary and metastatic liver cancers. Its investigational product is Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The design of this product is to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. OTCQB-listed, Delcath Systems is headquartered in New York, New York.

The Company has started a worldwide Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM). Delcath plans to initiate an international registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the United States.

Delcath’s system has been commercially available in Europe since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been utilized at major medical centers to treat a broad array of cancers of the liver. Liver directed high dose chemotherapy uses percutaneous hepatic perfusion (PHP) to deliver concentrated doses of a chemotherapeutic agent directly to the liver. Delcath Systems has supported clinical research of liver directed high dose chemotherapy in patients with metastatic ocular and cutaneous melanoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and hepatocellular carcinoma.

For the remainder of this year, Delcath Systems’ plan is to concentrate on advancing its clinical programs of its unique Melphalan/HDS, and also to propel commercialization efforts for CHEMOSAT in Europe. The Company continues its emphasis on the clinical trials, which consist of Clinical Development Program (CDP).

Delcath’s CDP comprises its FOCUS Phase 3 clinical trial of Melphalan/HDS in hepatic dominant OM (the FOCUS trial) as well as its intrahepatic cholangiocarcinoma (ICC) pivotal trial, scheduled to start enrollment by the end of this year.

Yesterday, Delcath Systems announced that the results of a single institution study were presented at the Cardiology and Interventional Radiology of Europe (CIRSE) annual meeting, taking place in Copenhagen, Denmark on September 16-20, 2017. The study is entitled” Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion (PHP) with Melphalan.”  This study was conducted by a team at the Leiden University Medical Center (LUMC) in Leiden, The Netherlands and presented by T.S. Meijer, MD.

Results of the study showed the GEN2 CHEMOSAT system had an overall efficiency of 86 percent.  Efficiency was highest at the time of highest concentration of melphalan in the blood and decreasing as melphalan blood concentration dropped. Peak efficiency was 95.4 percent in samples taken after 10 minutes of filtration, 85.9 percent at the end of the drug infusion period, and 77.5 percent at the end of the saline washout period. 

Delcath Systems, Inc. (DCTH), closed Wednesday's trading session at $0.0819, down 2.62%, on 13,100,723 volume with 1,142 trades. The average volume for the last 60 days is 3,667,230 and the stock's 52-week low/high is $0.015/$4.17.

Acorn Energy, Inc. (ACFN)

MegaPennyStocks, Catalyst IR, Marketbeat, Wall Street Resources, Wealthpire, Inc., SmarTrend Newsletters, and Hit and Run Candle Sticks reported earlier on Acorn Energy, Inc. (ACFN), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Acorn Energy, Inc. is a holding company listed on the OTCQB. It is a provider of machine-to-machine, Internet of Things (IoT) remote monitoring and control systems and services. Acorn has two portfolio companies: OmniMetrix and DSIT. Furthermore, Acorn Energy has started the process to liquidate the assets of its GridSense® subsidiary. GridSense® provides monitoring for all critical points along the electricity delivery system. Acorn Energy has its head office in Wilmington, Delaware.

The Company has an 80 percent equity stake in OmniMetrix. Acorn consolidates its assets, liabilities and results of operations. Acorn has a 41.2 percent equity stake in DSIT, which it accounts for under the equity method.

The Company’s OmniMetrix™ remotely monitors emergency back-up power generation systems to increase their reliability. OmniMetrix™ is the leader and pioneer in M2M wireless remote monitoring, control and diagnostics for pipelines and critical equipment.   

OmniMetrix is a solution for making critical systems more reliable. The Company is a solution for pipelines and critical facilities globally. This includes cell towers, medical facilities, data centers, public transportation systems, and federal, state, and municipal government facilities. 

Acorn Energy’s DSIT provides security solutions from underwater threats to naval and marine based energy assets. DSIT specializes in the science of sonar and underwater acoustics. It develops advanced Acoustic Intelligence (ACINT) measurement and analysis applications. The Company’s Shield™ family of Underwater Security Systems provides automatic Diver Detection Sonars for protection of valuable coastal and offshore sites. 

Last month, Acorn Energy announced results for its Q2 ended June 30, 2017. Mr. Jan H. Loeb, Acorn Energy’s President and Chief Executive Officer, said, "Our OmniMetrix remote monitoring and control business continued to achieve growth and margin expansion during the second quarter. OmniMetrix's second quarter margin of 57 percent represents a continuing trend of increasing margins for the Company. Meanwhile we are seeking to monetize our interest in DSIT in order to enhance our financial position and become a more focused company…”

Acorn Energy, Inc. (ACFN), closed Wednesday's trading session at $0.255125, down 4.20%, on 29,617 volume with 22 trades. The average volume for the last 60 days is 47,326 and the stock's 52-week low/high is $0.135/$0.5612.

Titan Medical, Inc. (TITXF)

OTC Markets reported on Titan Medical, Inc. (TITXF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Titan Medical, Inc. focuses on the design, development, and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS). Currently under development, the Company’s SPORT Surgical System includes a surgeon-controlled robotic platform that features multi-articulating instruments for performing MIS procedures by way of a single port. A medical device enterprise, Titan Medical has its head office in Toronto, Ontario. The Company lists on the OTC Markets’ OTCQB.

Titan Medical’s surgical system includes a workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and also provides a 3D high-definition endoscopic view inside a patient's body. The design of the SPORT system is to enable surgeons to perform a comprehensive set of general abdominal, gynecologic, urologic, and colorectal procedures. The design of the system is for improved clinical capabilities, operating room efficiency, and hospital economics. 

The SPORT Surgical System is an inventive single incision robotic surgical system. It has undergone development based on clinical user needs. It is covered by 14 patents and 37 pending applications. The SPORT Surgical System provides access to underserved market segments, such as ambulatory surgery centers. Concerning Open Display, the 3D high definition 32-inch display provides a first-rate balance of surgical immersion and situational awareness in the Operating Room (OR).

The Company has completed initial formative human factors studies for its SPORT single port robotic surgical system. Formative human factors studies involve the evaluation of prototypes by expert users, which focus on simulated task exercises vital to product safety. Titan Medical is planning to commercialize its single incision surgical system - first in Europe and subsequently the U.S.

This week, Titan Medical and Florida Hospital Nicholson Center announced the installation of Titan Medical's SPORT Surgical System at the hospital's training facility in Celebration, Florida. This is the initial installation in the world for pre-clinical feasibility and validation studies of the SPORT Surgical System.

Mr. David McNally, Titan Medical President and Chief Executive Officer, said, "We are thrilled to announce the first of three installations planned in U.S. and European Centers of Excellence in 2017. I am pleased with the focus and execution of our team as we deliver this first system ahead of our fourth quarter milestone projection. We look forward to beginning pre-clinical feasibility and validation studies in the coming weeks in a variety of surgical disciplines. Based on surgeon enthusiasm, we remain confident in the tremendous potential of single port robotic surgery to improve the physician experience as well as surgical outcomes."

Titan Medical, Inc. (TITXF), closed Wednesday's trading session at $0.156, down 1.89%, on 1,005,222 volume with 137 trades. The average volume for the last 60 days is 696,592 and the stock's 52-week low/high is $0.096/$0.55.

Where Food Comes From, Inc. (WFCF)

The Bowser Report, SmallCapVoice, Marketbeat, and Wyatt Investment Research reported earlier on Where Food Comes From, Inc. (WFCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Where Food Comes From, Inc. (d.b.a. IMI Global, Inc.) is a trusted resource for third party verification of food production practices. The Company supports greater than 10,000 farmers, ranchers, processors, retailers, distributors, and restaurants with a broad array of value-added services through its IMI Global, International Certification Services, Validus Verification Services, and Sterling Solutions units.  Where Food Comes From is headquartered in Castle Rock, Colorado.

The Company's Where Food Comes From® retail and restaurant labelling program uses the verification of product attributes to connect consumers to the sources of the food they purchase via product labelling and web-based information sharing and education. Utilizing QR code technology, consumers can speedily access information regarding the producers behind their food. 

Where Food Comes From has a solutions portfolio that encompasses beef, pork, poultry, lamb, dairy, eggs, and organic. The Company’s solutions portfolio includes offerings ranging from source and age, non-hormone and humane handling to organic, non-GMO (Genetically Modified Organism) and gluten free.  

Its Sterling Solutions is a foremost provider of third-party verification services in the western U.S. Sterling Solutions serves large dairies, calf ranches, and cattle operations. It has more than 10 years of on-farm auditing experience. Sterling Solutions operates as a wholly-owned subsidiary of Where Food Comes From. 

Where Food Comes From’s Validus Verification Services is a leader in independent certification of socially responsible production practices encompassing pork, poultry, as well as dairy products. Validus Verification Services is a wholly-owned subsidiary of the Company. 

Where Food Comes From has acquired a 60 percent interest in privately held SureHarvest, Inc. SureHarvest is a top provider of agri-food sustainability solutions. SureHarvest provides an extensive variety of sustainability and farming MIS solutions, certification and compliance management, and a host of professional services.  

Where Food Comes From has acquired privately held A Bee Organic, a USDA Accredited Certification Agency. A Bee Organic provides more than 125 customers with National Organic Program (NOP) certifications for hydroponic, aquaponic, in-ground and wild crops. This includes avocados, blueberries, citrus and stone fruits, greens, and manzanita.

Earlier this month,   Where Food Comes From (d.b.a. IMI Global) announced its role as exclusive provider of third-party verifications for Ben & Jerry's Caring Dairy Standards. Under the Caring Dairy Standards program, dairy farmers that supply Ben & Jerry's with milk and cream must comply with three core areas of focus. These are Cow Care, Planet Stewardship, and Farmer livelihoods.

Cow Care involves animal care, well-being and herd management. Planet Stewardship covers an assortment of sustainable farming techniques. Farmer Livelihoods ensures safe dignified conditions for all involved on the farm. Where Food Comes From will conduct on-farm audits with Ben and Jerry's dairy suppliers to confirm compliance to these standards.

Where Food Comes From, Inc. (WFCF), closed Wednesday's trading session at $2.45, up 4.26%, on 21,470 volume with 24 trades. The average volume for the last 60 days is 6,444 and the stock's 52-week low/high is $1.83/$2.6945.

Zoom Telephonics, Inc. (ZMTP)

OtcWizard, SmallCapVoice, FeedBlitz, Marketbeat, Wall Street Mover, and OTC Picks reported on Zoom Telephonics, Inc. (ZMTP), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Zoom Telephonics, Inc. is a leading manufacturer of cable modems and other communications products. It designs, produces, markets, and supports cable modems and other communications products under the Zoom, Hayes®, and Global Village® brands. Formed in 1977, Zoom Telephonics is based in Boston, Massachusetts.  

Zoom’s products include cable modems & gateways, dial-up modems, mobile broadband modems and routers, wireless networking products, ADSL gateways, Bluetooth wireless products, wireless keyboards, and ZoomGuard wireless sensors & controls. In addition, products include asymmetric digital subscriber line modems, wireless local area networking products, Voice Over IP products (VoIP), wired networking equipment, dialers and related telephony products, wireless sensors and controls, phone jacks and AC power adapters, and language-related specifics. 

Zoom Telephonics signed an exclusive license agreement in May of 2015 with Motorola Mobility LLC. The license agreement is for the Motorola brand in connection with consumer cable modem products. This includes cable modem bridges, cable modem/routers, and cable set-top boxes containing cable modems, for the United States and Canada. This agreement began on January 1, 2016 and runs through December 31, 2020.  

Zoom Telephonics has its new line of Motorola brand cable modems. Effective January 1, 2016, the Company, via its MTRLC division, commenced its exclusive 5-year license for producing Motorola brand cable modems and gateways.

This past June, The MTRLC LLC division of Zoom Telephonics announced it started selling its Motorola Model MR1900 router. This high-performance Wi-Fi router is available from top retailers and distributors in the United States and Canada, Europe, Latin America, and the Middle East.

The MR1900 provides a high-speed intelligent link between Wi-Fi and Ethernet devices and whatever Ethernet-capable modem is utilized for Internet access. The MR1900 features Wi-Fi Power Boost to deliver very high speeds and extended range. The Power Boost feature employs high-performance power amplifiers and a separate antenna for each of its 6 Wi-Fi channels. This is to deliver Wi-Fi power very close to the FCC's legal limit in the United States.

This month, Zoom Telephonics announced the signing of an amendment to its license agreement with Motorola Mobility to include the exclusive global rights for the Motorola brand for consumer-grade cellular modems and gateways, DSL modems and gateways, and MoCA (Multimedia over Coax) adapters. Furthermore, the amendment grants Zoom Telephonics non-exclusive global rights to use the Motorola brand for consumer-grade cellular home sensors that are products designed, marketed, and sold for use by consumers for their personal, family, or household use.

Zoom Telephonics, Inc. (ZMTP), closed Wednesday's trading session at $1.99, even for the day, on 71,487 volume with 58 trades. The average volume for the last 60 days is 5,896 and the stock's 52-week low/high is $1.46/$3.20.


The QualityStocks
Company Corner


Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.45, up 7.14%, on 207,040 volume with 101 trades. The stock’s average daily volume over the past 60 days is 87,495 and its 52-week low/high is $0.11/$0.699.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. The publication, entitled, "Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects," discusses the potential of cannabinoids as efficient treatment options. To view the full publication, visit: https://www.networknewswire.com/advances-drug-delivery-hold-promise-reducing-inevitable-side-effects/

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.7359, off by 0.55%, on 148,290 volume with 150 trades. The stock’s average daily volume over the past 60 days is 111,396 and its 52-week low/high is $0.6171/$0.90.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ABcann Global (TSX VENTURE: ABCN) (OTCQB: ABCCF), a client of NNW that is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis.The publication, titled, "What it Takes to Thrive in Canada's Multi-Billion-Dollar Marijuana Industry," highlights some of the top competitors in the flourishing Canadian marijuana market. To view the full publication, visit: https://www.networknewswire.com/takes-thrive-canadas-multi-billion-dollar-marijuana-industry/

Also today: ABcann Global Enters Its Growth Phase (Plus Exclusive Interview) -- CFN Media CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with ABcann Global Corporation's (TSX VENTURE: ABCN) (OTCQB: ABCCF) Aaron Keay, former CEO and current member of the Board of Directors. In the interview, Mr. Keay discusses the company's transition to new CEO Barry Fishman, as well as the opportunities ahead for the company in both Canada and internationally.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Enters Its Growth Phase (Plus Exclusive Interview) -- CFN Media

NetworkNewsWire Announces Publication on the Operations of Key Players in Canada's Legal Marijuana Market

ABcann Global Receives $11.9 Million from Exercise of Warrants

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.35, up 1.45%, on 656,486 volume with 213 trades. The stock’s average daily volume over the past 60 days is 342,966, and its 52-week low/high is $0.073/$0.72.

CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media

InMed Retains Consultant Ben Paterson for Biosynthesis Development

NetworkNewsWire Announces Publication Highlighting the Potential of Cannabinoid Biosynthesis

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.5345, off by 6.23%, on 126,408 volume with 77 trades. The stock’s average daily volume over the past 60 days is 69,874 and its 52-week low/high is $0.32/$2.75.

SmallCapVoice.com, Inc. and ChineseInvestors.com (OTCQB:CIIX) ("CIIX" or the "Company"), the premier financial information website for Chinese-speaking investors in both the U.S. and China, and a well-known cannabidiol (CBD) health brand engaged in the development, manufacturing, marketing and distribution of consumer products containing CBD, today announce that the Company’s director of investor relations, Alan Klitenic, is featured in an audio interview at SmallCapVoice.com. The interview outlining CIIX’s current news and efforts can be heard at http://smallcapvoice.com/blog/9-18-17-smallcapvoice-interview-with-chineseinvestors-com-inc-ciix.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

Alan Klitenic, Director of Investor Relations for ChineseInvestors.com, Discusses Recent CIIX News and Industry Trends in a New Audio Interview with SmallCapVoice.com

ChineseInvestors.com, Inc.'s Wholly Owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Completes the Record Filing Process with the China FDA, Expects to Launch its Hemp Infused Skin Care Line in October

NetworkNewsWire Announces Publication on Cannabis Investment Options

AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.0158, up 30.58%, on 46,058 volume with 7 trades. The stock’s average daily volume over the past 60 days is 177,182 and its 52-week low/high is $0.002/$0.13.

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with AppSwarm, Inc. (SWRM)

AppSwarm, Inc. (SWRM) Engages NetworkNewsWire for Corporate Communications Solutions

AppSwarm Announces Acquisition of Multiplatform Games Developer and Publisher MediaPlay and the Creation of Two Divisions of AppSwarm, Inc.


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Trader Power News
(PZRX) +66.45%


(ALNY) +51.71%


(HIVE.V) +63.79%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251